Skip to main content
Premium Trial:

Request an Annual Quote

New Leaders Appointed at Ernst & Young's Global Biotechnology Center

Premium
Ernst & Young has named Glen Giovanetti leader of its new Global Biotechnology Center in Boston, and appointed Scott Sarazen to the new position of global markets leader within the center. The biotech center connects E&Y professionals worldwide, enabling them to share their experience and information on current and emerging industry issues.
 
Giovanetti was previously business risk services leader for E&Y’s Pacific North West area. He has experience assisting biotechnology and medical device clients with strategic transactions including initial public offerings, public and private debt offerings, technology licensing and R&D contracts, and acquisitions.
 
Sarazen, who recently joined Ernst & Young, brings more than 18 years of private and public sector biotechnology industry experience to the firm. His previous positions include senior vice president for life sciences with the Massachusetts Development Finance Agency and director of global planning and development at Genzyme.
 
Ernst & Young issues Beyond Borders, an annual biotechnology report. The 2007 edition was released in April.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.